C. Logothetis

4.7k total citations · 1 hit paper
71 papers, 2.4k citations indexed

About

C. Logothetis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, C. Logothetis has authored 71 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 18 papers in Surgery. Recurrent topics in C. Logothetis's work include Prostate Cancer Treatment and Research (38 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Testicular diseases and treatments (10 papers). C. Logothetis is often cited by papers focused on Prostate Cancer Treatment and Research (38 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Testicular diseases and treatments (10 papers). C. Logothetis collaborates with scholars based in United States, Spain and France. C. Logothetis's co-authors include Avishay Sella, F. H. Dexeus, R. J. Amato, Robert G. Kilbourn, Alberto G. Ayala, Laura Finn, Randall E. Millikan, Douglas E. Johnson, Andrew C. von Eschenbach and David A. Swanson and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

C. Logothetis

71 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

1990 463 citations C. Logothetis, F. H. Dexeus et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Logothetis United States	23	1.1k	1.0k	817	690	403	71	2.4k
C.J. van Groeningen Netherlands	22	590 0.5×	1.0k 1.0×	1.1k 1.3×	522 0.8×	208 0.5×	49	2.4k
Avishay Sella United States	32	1.8k 1.6×	1.8k 1.8×	1.2k 1.5×	860 1.2×	517 1.3×	105	3.6k
R. J. Amato United States	20	943 0.9×	816 0.8×	588 0.7×	779 1.1×	442 1.1×	68	2.0k
Wendy Recant United States	23	485 0.4×	539 0.5×	972 1.2×	764 1.1×	559 1.4×	47	2.4k
D. Fennelly Ireland	25	564 0.5×	878 0.9×	1.8k 2.2×	417 0.6×	377 0.9×	85	2.6k
Andreas H. Marx Germany	26	822 0.8×	583 0.6×	1.3k 1.6×	698 1.0×	301 0.7×	75	2.2k
O. Kisker Germany	28	876 0.8×	555 0.6×	2.0k 2.5×	988 1.4×	620 1.5×	43	3.3k
Joseph T. Spaulding United States	14	1.5k 1.4×	610 0.6×	459 0.6×	406 0.6×	259 0.6×	21	2.3k
Jacqueline Vuky United States	25	681 0.6×	1.4k 1.4×	1.4k 1.8×	565 0.8×	279 0.7×	64	2.6k
Masao Kameyama Japan	31	1.1k 1.0×	930 0.9×	1.3k 1.6×	1.3k 1.9×	384 1.0×	158	3.4k

Countries citing papers authored by C. Logothetis

Since Specialization

Citations

This map shows the geographic impact of C. Logothetis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Logothetis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Logothetis more than expected).

Fields of papers citing papers by C. Logothetis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Logothetis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Logothetis. The network helps show where C. Logothetis may publish in the future.

Co-authorship network of co-authors of C. Logothetis

This figure shows the co-authorship network connecting the top 25 collaborators of C. Logothetis. A scholar is included among the top collaborators of C. Logothetis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Logothetis. C. Logothetis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fizazi, Karim, Gwénaël Le Teuff, Aude Fléchon, et al.. (2024). Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. 42(28). 3270–3276. 4 indexed citations

Halabi, Susan, Catherine M. Tangen, Mark Rosenthal, et al.. (2020). Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. Annals of Oncology. 31(7). 930–941. 13 indexed citations

Kim, Jae Hwan, Renata Pasqualini, Wadih Arap, et al.. (2008). A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 27(39). 5195–5203. 29 indexed citations

Yang, Jun, Elba S. Vázquez, Funda Vakar‐Lopez, et al.. (2007). Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 27(5). 596–603. 51 indexed citations

Subbarayan, Vemparala, Peter Krieg, Linda C. Hsi, et al.. (2006). 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor γ. Oncogene. 25(44). 6015–6025. 21 indexed citations

Logothetis, C.. (2003). The case for a biologically based classification of prostate cancer. Seminars in Oncology. 30(5). 562–566. 1 indexed citations

Schumacher, Guido, Elizabeth Bruckheimer, A. Beham, et al.. (2001). Molecular determinants of cell death induction following adenovirus‐mediated gene transfer of wild‐type p53 in prostate cancer cells. International Journal of Cancer. 91(2). 159–166. 20 indexed citations

Millikan, Randall E., William Plunkett, Terry Smith, Dallas Williams, & C. Logothetis. (2001). Gemcitabine modulation of alkylator therapy. Cancer. 92(1). 194–199. 13 indexed citations

Horti, J, Shannon C. Dixon, C. Logothetis, et al.. (1999). Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. British Journal of Cancer. 79(9-10). 1588–1593. 23 indexed citations

10.

Hutter, R. V. P., James E. Montie, Christer Busch, et al.. (1996). Workgroup 3: Current prognostic factors and their relevance to staging. Cancer. 78(2). 369–371. 8 indexed citations

11.

Aulitzky, W. E., Walter E. Aulitzky, Julie A. Ellerhorst, et al.. (1995). Intermittent Low-Dose IFN Gamma Treatment for Metastatic Renal Cell Carcinoma: Analysis of Factors Predicting Clinical Response and Long-Term Survival. Oncology Research and Treatment. 18(4). 339–345. 2 indexed citations

12.

Amato, R. J., Christina Meyers, Julie A. Ellerhorst, et al.. (1995). A phase I trial of intermittent high-dose α-interferon and dexamethasone in metastatic renal cell carcinoma. Annals of Oncology. 6(9). 911–914. 18 indexed citations

13.

Sella, Avishay, Robert G. Kilbourn, R. J. Amato, et al.. (1994). Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.. Journal of Clinical Oncology. 12(4). 683–688. 96 indexed citations

14.

Dimopoulos, Meletios Α., C. Logothetis, Avi B. Markowitz, et al.. (1993). Collecting Duct Carcinoma of the Kidney. British Journal of Urology. 71(4). 388–391. 100 indexed citations

15.

Dexeus, F. H., et al.. (1990). Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 8(2). 325–329. 88 indexed citations

16.

Logothetis, C., F. H. Dexeus, Laura Finn, et al.. (1990). A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.. Journal of Clinical Oncology. 8(6). 1050–1055. 463 indexed citations breakdown →

17.

Logothetis, C.. (1990). The case for relevant staging of germ cell tumors. Cancer. 65(S3). 709–717. 6 indexed citations

18.

Têtu, Bernard, Jae Y. Ro, Alberto G. Ayala, et al.. (1989). Small cell carcinoma of prostate associated with myasthenic (eaton-lambert) syndrome. Urology. 33(2). 148–152. 44 indexed citations

19.

Logothetis, C., Douglas E. Johnson, Clayton Chong, et al.. (1988). Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update.. Journal of Clinical Oncology. 6(10). 1590–1596. 119 indexed citations

20.

Logothetis, C., Antonio Trindade, & M. L. Samuels. (1982). Sequential chemotherapy with cytoxan, adriamycin, and cis-platinum alternating with velban-bleomycin for stage III germinal cancer with poor prognosis. Proceedings of the American Association for Cancer Research. 23. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact